<DOC>
	<DOCNO>NCT02079376</DOCNO>
	<brief_summary>Study evaluate efficacy gastric stimulation ( GCM ) use DIAMOND System improvement glycemic control measure change HbA1c . Relationship blood TG level GCM efficacy evaluate .</brief_summary>
	<brief_title>The DIAMOND® Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject 18 70 year age Body mass index &gt; 30 &lt; 45 ( kg/m2 ) Type 2 diabetes duration least 6 month Type 2 diabetic subject treat oral antidiabetic agent [ Sulfonylurea , Metformin , thiazolinedione ( TZD ) DPP4 inhibitor ] Stable antidiabetic medication least 3 month prior enrollment , six month thiazolinedione ( TZD ) The subject routine diabetes care investigator another single physician supply medical record least 6 month prior enrollment HbA1c 7.3 % ≤ 9.5 % Visit 1 Stable HbA1c , define significant change ( variation ≤ 0.5 % ) historical value record subject 's medical record within 3 month prior enrollment HbA1c gather Visit 1 . Fasting blood glucose &gt; 120 &lt; 350 mg/dl Visit 1 . Women childbearing potential ( i.e. , postmenopausal surgically sterilize ) must agree use adequate birth control method Stable weight , define significant weight change ( variation &lt; 3 % ) within three month prior enrollment document subject 's medical record . For subject treat thiazolinedione , stable weight within six month . If taking thesis medication , sable antihypertensive lipidlowering medication least one month prior enrollment If subject antidepressant medication treatment need stable least six month prior enrollment . Ability willingness perform require study data collection procedure adhere operate requirement DIAMOND System Willingness perform least four ( 3 ) capillary blood glucose test per day twice week duration study Willingness refrain use prescription , counter herbal weight loss product duration trial Alert , mentally competent , able understand willing comply requirement clinical trial , personally motivate abide requirement restriction clinical trial Able provide voluntary inform consent Insulin therapy last 3 month Taking GLP1 agonist last 3 month enrollment Currently take fibrates , nicotinamide omega 3 fatty acid antilipidemic treatment Subjects EF le 35 % otherwise indicate ICD Taking medication know affect gastric motility narcotic ( chronic use ) anticholinergics/antispasmodics Experiencing severe progress diabetic complication ( i.e . retinopathy stabilize , nephropathy macroalbuminuria ) Prior wound heal problem due staphylococcus candida Diagnosed past current psychiatric condition may impair ability comply study procedure Use antipsychotic medication Diagnosed eat disorder bulimia binge eat Obesity due endocrine disorder ( e.g . Cushing disease ) Pregnant lactate Diagnosed impaired liver function ( liver enzymes 3 time great normal ) Any prior bariatric surgery Any history pancreatitis Any history peptic ulcer disease within 5 year enrollment Diagnosed gastroparesis Use active medical device ( either implantable external ) ICD , pacemaker , drug infusion device , neurostimulator ( either implant worn ) . Subjects use external active device able willing avoid use device study may enrol . Cardiac history physician feel exclude subject study . Use another investigator device agent 30 day prior enrollment A history lifethreatening disease within 5 year enrollment Change diabetic medication Visit 1 Visit 3 . Any additional condition ( ) Investigator 's opinion would warrant exclusion study prevent subject completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>diabetes</keyword>
</DOC>